BIOHIT HealthCare     
必欧瀚(Biohit)公司致力研制和生产在医疗领域、研究领域及商业实验室中使用的移液器产品与体外诊断检测系统必欧瀚(Biohit)公司的诊断产品范围包括GastroPanel和GastroView检测，通过采集病人血液样品，对幽门螺杆菌感染和萎缩性胃炎进行检测，并能对胃癌、消化性溃疡、胃食管返流及其并发症(维生素B12、钙和铁缺乏)、Barrett食管病等进行快速筛查。
必欧瀚(Biohit)可提供多种ELISA检测，乳糖不耐症和幽门螺杆菌感染快速检测以及结肠癌筛查层析法快速检测。必欧瀚(Biohit)还开发和制造适用于癌症诊断的单克隆抗体，并可以用于制造免疫诊断试剂盒。
除了移液器和诊断试剂，必欧瀚(Biohit)的产品范围还包括适用于免疫测定分析的各种酶标仪洗板机和软件。必欧瀚(Biohit)还可提供检测仪器维护、校准和培训服务以及进行诊断检测的服务实验室。
必欧瀚(Biohit)产品的新增项目包括用于消除来自胃肠道和食品的致癌乙醛的功能性食品。必欧瀚(Biohit)公司总部位于芬兰首都赫尔辛基，制造工厂位于芬兰的科亚尼及赫尔辛基。必欧瀚(Biohit)公司已于1999年在赫尔辛基证券交易所(OMX-Helsinki)上市(BIOBV)。
历史背景
自上世纪七十年代，必欧瀚(Biohit)公司现任管理者与杰出员工，芬兰Labsystems(1971年)、Eflab(1978年)及必欧瀚(Biohit) (1988年)创始人Osmo-Suovaniemi教授(M.D,-Ph.D)进行了下列发明，并且使发明商业化：
• 9、8及12道可调式微量移液器。
• 3×3及8×12孔平底微孔板，在每个孔的底部设计了光学窗孔，作为免疫分析时的固相物质使用。
• 垂直光测量原理(垂直光路光度学、浊度分析法、荧光比色法及荧光测定法)，以及应用此项发明生产的设备，如最早的96孔板阅读器Titertek Multiskan(1978)。
• 以微孔板为基础的酶联免疫测定，比如结肠直肠癌及HIV诊断与筛选试剂盒，以及早在上试剂80年代就已发明使用的TORCH-组检测试剂盒等。
如今，必欧瀚(Biohit)公司与多通道液体操作技术、微孔板及垂直光测定技术相关的发明已被成功地在全球范围内广泛应用，从而已被公认为全球行业标准。上述发明也在全球范围内掀起了实验室常规改革的高潮。
从上世纪80年代开始，必欧瀚(Biohit)公司继续开展在垂直光测量工具与微量培养板应用领域的研究与开发。以多通道液体操作及垂直测量工具为基础的设备与分析系统，大大拓宽了

Biohit HealthCare is a globally operating biotechnology company that develops, manufactures and markets diagnostic tests and analysis systems.

Our products are used by research and health care worldwide.
Established in 1988 by Professor Osmo Suovaniemi
Business area: Diagnostics
Headquartered in Finland, Helsinki
Subsidiaries located in China and UK
Production plant ís located in Finland
Biohit's products are sold by many distributors around the world
Biohit Plc's share (BIOBV) is quoted on NASDAQ OMX Helsinki since June1999, Small cap/Healthcare

Innovations and patents

Biohit HealthCare's operations are based on a goal-oriented and long-term innovation and patenting strategy. Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations that can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract.

Diagnostics

Biohit HealthCare has products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. The Acetium innovation was developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. The key objective of the diagnostics business is to prevent diseases of the gastrointestinal tract.

Biohit Group worldwide

The Biohit Group employs around 35 people in four countries. The company is headquartered in Helsinki, Finland, and has subsidiary in the UK. Additionally, Biohit's products are sold by many distributors around the world.

Biohit Plc. on the stock exchange

Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare since 1999. More information about the share and financials is available in the Investors section of this site.